Vanda Pharmaceuticals Stock Forecast, Price & News

-1.56 (-8.73 %)
(As of 07/30/2021 04:57 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume2.49 million shs
Average Volume499,074 shs
Market Capitalization$906.25 million
P/E Ratio28.61
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive VNDA News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Vanda Pharmaceuticals logo

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.00 out of 5 stars

Medical Sector

544th out of 2,216 stocks

Pharmaceutical Preparations Industry

274th out of 869 stocks

Analyst Opinion: 2.3Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions

Is Vanda Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vanda Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vanda Pharmaceuticals stock.
View analyst ratings for Vanda Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Vanda Pharmaceuticals?

Wall Street analysts have given Vanda Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vanda Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Vanda Pharmaceuticals' next earnings date?

Vanda Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, October 27th 2021.
View our earnings forecast for Vanda Pharmaceuticals

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its quarterly earnings data on Wednesday, July, 28th. The biopharmaceutical company reported $0.17 EPS for the quarter, hitting the Thomson Reuters' consensus estimate of $0.17. Vanda Pharmaceuticals had a net margin of 12.46% and a trailing twelve-month return on equity of 7.03%.
View Vanda Pharmaceuticals' earnings history

How has Vanda Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Vanda Pharmaceuticals' stock was trading at $10.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, VNDA shares have increased by 54.1% and is now trading at $16.33.
View which stocks have been most impacted by COVID-19

What guidance has Vanda Pharmaceuticals issued on next quarter's earnings?

Vanda Pharmaceuticals updated its FY 2021 earnings guidance on Wednesday, July, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $270 million-$300 million, compared to the consensus revenue estimate of $282.92 million.

What price target have analysts set for VNDA?

3 brokers have issued 12 month price targets for Vanda Pharmaceuticals' shares. Their forecasts range from $14.00 to $22.00. On average, they expect Vanda Pharmaceuticals' stock price to reach $18.00 in the next twelve months. This suggests a possible upside of 10.2% from the stock's current price.
View analysts' price targets for Vanda Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the following people:
  • Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 61, Pay $1.44M)
  • Mr. Kevin Patrick Moran, Sr. VP, CFO & Treasurer (Age 37, Pay $755.63k)
  • Mr. Timothy Williams, Sr. VP, Gen. Counsel & Sec. (Age 45, Pay $641.55k)
  • Mr. Aranthan Jones II, Chief Corp. Affairs & Communications Officer (Age 45, Pay $640.8k)
  • Mr. Joakim Wijkstrom, Sr. VP & Chief Marketing Officer (Age 55, Pay $786.37k)
  • Mr. Scott L. Howell, Chief People Officer
  • Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 51)
  • Ms. Elizabeth Van Every, Head of Corp. Affairs

What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO?

12 employees have rated Vanda Pharmaceuticals CEO Mihael H. Polymeropoulos on Mihael H. Polymeropoulos has an approval rating of 24% among Vanda Pharmaceuticals' employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Vanda Pharmaceuticals' key competitors?

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.07%) and North Star Investment Management Corp. (0.01%). Company insiders that own Vanda Pharmaceuticals stock include Aranthan Jones II, Gian Piero Reverberi, Gunther Birznieks, James Patrick Kelly, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Thomas Watkins and Timothy Williams.
View institutional ownership trends for Vanda Pharmaceuticals

Which institutional investors are selling Vanda Pharmaceuticals stock?

VNDA stock was sold by a variety of institutional investors in the last quarter, including North Star Investment Management Corp.. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Aranthan Jones II, Gunther Birznieks, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Thomas Watkins, and Timothy Williams.
View insider buying and selling activity for Vanda Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Vanda Pharmaceuticals stock?

VNDA stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue.
View insider buying and selling activity for Vanda Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $16.33.

How much money does Vanda Pharmaceuticals make?

Vanda Pharmaceuticals has a market capitalization of $907.36 million and generates $248.17 million in revenue each year. The biopharmaceutical company earns $23.34 million in net income (profit) each year or $0.42 on an earnings per share basis.

How many employees does Vanda Pharmaceuticals have?

Vanda Pharmaceuticals employs 292 workers across the globe.

What is Vanda Pharmaceuticals' official website?

The official website for Vanda Pharmaceuticals is

Where are Vanda Pharmaceuticals' headquarters?

Vanda Pharmaceuticals is headquartered at 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]

This page was last updated on 7/30/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.